课题基金 / 基金详情

LONG TERM SAFETY & EFFICACY OF LANREOTIDE FOR TREATMENT OF ACROMEGALICS

LONG TERM SAFETY & EFFICACY OF LANREOTIDE FOR TREATMENT OF ACROMEGALICS
长期安全
批准号：
6305835
负责人：
DAVID L KLEINBERG
金额：
$2.1万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6305835
关键词：
acromegaly clinical research drug adverse effect drug screening /evaluation endocrine disorder chemotherapy hormone therapy human subject human therapy evaluation insulinlike growth factor peptide hormone analog somatostatin somatotropin

项目摘要

项目成果

DAVID L KLEINBERG的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The objectives of this open-label trial are to investigate the long-term safety and efficacy of lanreotide (IPSTYL) in the treatment of acromegaly by using normalization of GH and IGF-1 levels to guide dosing. Subjects must have been enrolled in a prior trial of IPSTYL. Secondary objectives are to investigate the efficacy and safety of IPSTYL in terms of tumor response, ability to control/reduce symptoms of acromegaly, adverse events and normalization of IGF-1 levels in a group of patients who have near normal levels.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SURGICAL DEBULKING PLUS OCTREOTIDE VERSUS OCTREOTIDE ALONE IN ACROMEGALY
PREVALENCE OF GROWTH HORMONE DEFICIENCY & RANGES OF IGF-1 IN NORMAL ELDERLY
PREVALENCE OF GROWTH HORMONE DEFICIENCY & RANGES OF IGF-1 IN NORMAL ELDERLY
Prevalence of Growth Hormone Deficiency & Ranges of IGF-1 in Normal Elderly
海外基金